Statera Biopharma dropped by accounting firm

FORT COLLINS — Statera Biopharma Inc. (Nasdaq: STAB) is without a registered independent accounting agency after its auditor resigned last week, according to documents filed with the U.S. Securities and Exchange Commission.

The agency, Dallas-based Turner, Stone & Co. LLP, informed Statera of its resignation April 11. Its resignation letter, which was filed with the SEC, did not contain any reasoning other than “information that has come to our attention.”

Last week, Statera also sold the rights to produce the cancer drug Entolimod to Wexford, Pennsylvania, company Coeptis Therapeutics Inc. for $6 million. Statera CEO Mike Handley said in a statement…